RxDoctor Payments Data

Sukesh Manthri, MD

Internal Medicine · Houma, LANPI 1508271859

Payments from drug & device makers

$7,288in general payments, 2019–2025

Across 44 payments — averaging $165.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2K
  • AstraZeneca$2K
  • Novartis$2K
  • E.r. Squibb & Sons, L.L.C.$375
  • Merck$201
  • Tactile Systems Technology Inc$49
  • plus $114 from 6 others

What the payments were for

  • Consulting fees$1,92043%
  • Food & beverage$66015%
  • Education$381%
  • Other$1,87942%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,288 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$66,254
Medicare patients
282
Services billed
701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide36$727,006
XtandiEnzalutamide28$436,380
BrukinsaZanubrutinib21$325,732
CalquenceAcalabrutinib Maleate18$258,717
NubeqaDarolutamide14$190,042
Imatinib Mesylate13$86,441
EliquisApixaban31$19,174
Abiraterone Acetate25$13,630
Exemestane22$3,295
Letrozole114$2,503
Anastrozole49$1,506
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$1,267
Dexamethasone26$1,074
ValacyclovirValacyclovir Hcl12$814
Tamoxifen Citrate46$712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$14$436,38028 claims
AstraZenecaCalquence$2,244$258,71718 claims
PfizerEliquis$21$19,17431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Houma

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →